Search company, investor...
Treventis company logo


Founded Year



Grant - II | Alive

Total Raised


Last Raised

$2.97M | 7 mos ago

About Treventis

Treventis is a biotechnology company. It utilizes a discovery engine common conformational morphology (CCM) to identify druggable active sites in misfolded protein targets. It combines unique in silico models with deep expertise in model development to enable rational drug design against misfolded protein targets. It was founded in 2008 and is based in Dover, Delaware.

Headquarters Location

1111B South Governors Avenue

Dover, Delaware, 19904,

United States

(416) 603-5800 x2975

Missing: Treventis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Treventis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Treventis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Treventis is included in 2 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,623 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Biopharma Tech

1,568 items

Treventis Patents

Treventis has filed 5 patents.

The 3 most popular patent topics include:

  • Alzheimer's disease
  • Drug discovery
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Alzheimer's disease, G protein coupled receptors, Clusters of differentiation, Neurological disorders, Dementia


Application Date


Grant Date



Related Topics

Alzheimer's disease, G protein coupled receptors, Clusters of differentiation, Neurological disorders, Dementia



Latest Treventis News

Tech Update: A new approach to Alzheimer’s and proof that video calls are exhausting

Apr 24, 2023

updateArticle was updated 13 mins ago Small Canadian biotech start up Treventis is playing in the big leagues. The Toronto company just secured a partnership with Takeda, Japan’s largest drug marker, to help develop a new therapy for Alzheimer’s. There’s still uncertainty around the causes of Alzheimer’s, but misfolding of a protein called tau is thought to play an important role. It is believed that misfolded tau proteins can build up in the neurons of the brain and kill them. As neurons die, the patient’s ability to think and remember becomes impaired. Treventis has built a software platform that creates computer models of how these proteins misfold. Christopher Barden, Treventis’s CEO, says these simulations allow its scientists to work out where potential drugs could attach to the protein and stop them from accumulating. Barden says Treventis has “identified a class of compounds that are particularly well-suited to affecting tau.” Takeda and Treventis will figure out which of these compounds have the most potential and then take them into lab and clinical tests. Scientists have made some progress in understanding Alzheimer’s in recent years, but effective treatments remain elusive. “There’s certainly an unmet medical need,” says Barden. “We like the challenge.” New innovation centre set for Kitchener The University of Waterloo and Velocity incubator have broken ground on a new purpose-built space in downtown Kitchener to help fast track local entrepreneurs and accelerate commercialization. The new Innovation Arena will feature collaborative spaces aimed at inspiring partnerships and facilitating exchanges between businesses, founders, researchers and the community. No surprise here: Zoom meetings are exhausting New research from York University proves what we’ve all suspected: Zoom meetings are more difficult and taxing than ones in real life. The researchers found that the visual cues we rely on when communicating in-person — like eye contact — become misleading on video platforms, making it harder to know when it’s your turn to speak. Miovision acquires Global Traffic Technologies Miovision, a Kitchener-based smart city equipment vendor, has acquired American company Global Traffic Technologies. Global sells software that enables emergency vehicles to switch traffic lights to green when they approach intersections. Sampler snaps up Abeo Canadian product sampling startup Sampler has acquired Abeo, a digital sampling agency for beauty products. The acquisition will deepen Sampler’s expertise in the beauty sector and accelerate its expansion into Europe and the U.S., where Abeo currently has offices. Good news, Einstein — you’re still right Einstein’s theory of general relativity, now over 100 years old, still checks out. That’s according to researchers at an international collaboration of astronomers, including some from the University of Toronto. Using the Atacama Cosmology Telescope in Chile, they created the most detailed map ever of the distribution of dark matter — and it aligns with what Einstein posited back in 1915. By the numbers $30 million: Toronto-based EV changing software company ChargeLab has raised $30 million in series A funding, including a $15 million investment from investors Eaton and Silver Comet, both big players in the EV charging game. $21 million: Mila , a Montreal-based AI institute, just received $21 million from Quebec’s provincial government to advance the institute’s work on socially beneficial AI. 1.8 per cent: Canada’s greenhouse gas emissions rose by 1.8 per cent in 2021. That’s a smaller-than-expected increase and takes us about a quarter of the way to the federal 2030 emissions reduction goal. $3 million: Dispersa , a startup that transforms food waste into biosurfactants (a type of sustainable cleaner), has cleaned up with a $3-million pre-seed funding round. Rebecca Gao writes about technology for MaRS . Torstar, the parent company of the Toronto Star, has partnered with MaRS to highlight innovation in Canadian companies. SHARE: Disclaimer This content was produced as part of a partnership and therefore it may not meet the standards of impartial or independent journalism.

Treventis Frequently Asked Questions (FAQ)

  • When was Treventis founded?

    Treventis was founded in 2008.

  • Where is Treventis's headquarters?

    Treventis's headquarters is located at 1111B South Governors Avenue, Dover.

  • What is Treventis's latest funding round?

    Treventis's latest funding round is Grant - II.

  • How much did Treventis raise?

    Treventis raised a total of $7.37M.

  • Who are the investors of Treventis?

    Investors of Treventis include U.S. Department of Defense, JLabs and Wellcome Trust.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.